HC Wainwright Has Pessimistic Outlook of ALDX Q3 Earnings

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Investment analysts at HC Wainwright reduced their Q3 2025 earnings per share (EPS) estimates for shares of Aldeyra Therapeutics in a report released on Monday, August 11th. HC Wainwright analyst M. Caufield now forecasts that the biotechnology company will post earnings of ($0.16) per share for the quarter, down from their prior forecast of ($0.12). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics’ Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.67) EPS, FY2026 earnings at ($0.13) EPS, FY2027 earnings at $0.43 EPS and FY2028 earnings at $0.83 EPS.

Separately, Wall Street Zen raised Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 21st.

Aldeyra Therapeutics Trading Up 0.2%

ALDX opened at $5.37 on Wednesday. The firm has a market cap of $321.66 million, a price-to-earnings ratio of -6.32 and a beta of 0.76. Aldeyra Therapeutics has a 12 month low of $1.14 and a 12 month high of $7.20. The stock has a fifty day moving average price of $4.30 and a 200-day moving average price of $4.25.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.05.

Insider Activity at Aldeyra Therapeutics

In other news, insider Stephen Machatha sold 22,073 shares of the business’s stock in a transaction on Monday, August 11th. The stock was sold at an average price of $5.15, for a total value of $113,675.95. Following the completion of the transaction, the insider directly owned 221,799 shares of the company’s stock, valued at approximately $1,142,264.85. The trade was a 9.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 9.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Panagora Asset Management Inc. increased its position in Aldeyra Therapeutics by 42.8% during the 2nd quarter. Panagora Asset Management Inc. now owns 72,059 shares of the biotechnology company’s stock valued at $276,000 after buying an additional 21,605 shares in the last quarter. Rhumbline Advisers increased its position in Aldeyra Therapeutics by 2.7% during the 2nd quarter. Rhumbline Advisers now owns 77,494 shares of the biotechnology company’s stock valued at $297,000 after buying an additional 2,018 shares in the last quarter. Intech Investment Management LLC increased its position in Aldeyra Therapeutics by 27.6% during the 2nd quarter. Intech Investment Management LLC now owns 29,983 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 6,477 shares in the last quarter. King Wealth Management Group acquired a new position in Aldeyra Therapeutics during the 2nd quarter valued at about $46,000. Finally, Geode Capital Management LLC increased its position in Aldeyra Therapeutics by 0.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,146,597 shares of the biotechnology company’s stock valued at $4,392,000 after buying an additional 8,769 shares in the last quarter. 59.71% of the stock is owned by institutional investors and hedge funds.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.